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To the editor
I read with great interest the article by Andukuri et al in a recent issue of your journal.1 
The article makes compelling reading. Interestingly, research over the past few years 
has shown that in addition to its significant diabetic-modulating effects, alogliptin also 
exerts significant direct antiatherosclerotic effects.
For instance, alogliptin decreases plasma nonesterified fatty acid levels by 11%.2 It 
simultaneously has an attenuating effect on serum triglyceride levels, decreasing them 
by almost 24%. Similarly, Monami et al in a recent meta-analysis reported that aloglip-
tin is associated with a significant attenuation in total serum cholesterol.3 Alogliptin 
also significantly decreases postprandial very low-density lipoprotein and chylomicron 
levels.4 Alogliptin mediates its antiatherosclerotic effects by decreasing expression of 
interleukin-1β and interleukin-6, which is typically enhanced in diabetes.5 It also has 
an attenuating effect on extracellular signal-regulated kinase-mediated expression of 
metalloproteinases 1 and 12.6 This exerts a significant inhibitory effect on macrophage-
modulated inflammation and thereby attenuates vascular atherosclerosis.
Interestingly, these hypolipidemic effects of alogliptin are markedly enhanced 
when used in combination with pioglitazone. For instance, alogliptin with adjunctive 
pioglitazone therapy decreases plasma nonesterified fatty acid levels by 25%–48% and 
serum triglyceride levels by 67%–77%.2,7 Alogliptin clearly exerts significant antiath-
erosclerotic and hypolipidemic effects, and may go a long way towards attenuating 
atherosclerosis-related morbidity and mortality in patients with diabetes as well as 
the metabolic syndrome.
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The letter by Dr Kapoor points out useful data in animal 
models. The current long-term cardiac outcome trials of 
alogliptin will be essential to determine the effect of this 
agent on the atherosclerotic process in man.
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